Amicus Therapeutics Inc. (FOLD) and Gamida Cell Ltd. (NASDAQ:GMDA) Contrasting side by side

This is therefore a comparing of the profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation in Amicus Therapeutics Inc. (NASDAQ:FOLD) and Gamida Cell Ltd. (NASDAQ:GMDA). The two are both Biotechnology companies that compete with one another.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Amicus Therapeutics Inc. 12 16.86 N/A -2.15 0.00
Gamida Cell Ltd. 7 0.00 N/A -2.47 0.00

Table 1 demonstrates Amicus Therapeutics Inc. and Gamida Cell Ltd.’s gross revenue, earnings per share (EPS) and valuation.


Table 2 hightlights the return on equity, net margins and return on assets of the two companies.

Net Margins Return on Equity Return on Assets
Amicus Therapeutics Inc. 0.00% -94.9% -52.1%
Gamida Cell Ltd. 0.00% -662.4% -130.2%


Amicus Therapeutics Inc. has a Current Ratio of 7.3 and a Quick Ratio of 7.2. Competitively, Gamida Cell Ltd.’s Current Ratio is 6.5 and has 6.5 Quick Ratio. Amicus Therapeutics Inc.’s better ability to pay short and long-term obligations than Gamida Cell Ltd.

Analyst Recommendations

The next table highlights the shown recommendations and ratings for Amicus Therapeutics Inc. and Gamida Cell Ltd.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Amicus Therapeutics Inc. 0 0 0 0.00
Gamida Cell Ltd. 0 0 1 3.00

Meanwhile, Gamida Cell Ltd.’s average price target is $16, while its potential upside is 248.58%.

Insider & Institutional Ownership

Roughly 0% of Amicus Therapeutics Inc. shares are owned by institutional investors while 13.1% of Gamida Cell Ltd. are owned by institutional investors. Insiders owned 0.9% of Amicus Therapeutics Inc. shares. On the other hand, insiders owned about 65.61% of Gamida Cell Ltd.’s shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Amicus Therapeutics Inc. -1.9% -0.4% -7.53% 6.26% -13.23% 29.44%
Gamida Cell Ltd. -5.13% -27.31% -51.06% -74.27% 0% -62.78%

For the past year Amicus Therapeutics Inc. had bullish trend while Gamida Cell Ltd. had bearish trend.


On 7 of the 8 factors Amicus Therapeutics Inc. beats Gamida Cell Ltd.

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. Its principal product is the migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which has completed two global Phase III registration studies. The company is also developing SD-101, which is in Phase III clinical study for the treatment of the genetic connective tissue disorder epidermolysis bullosa; and AT3375 to treat Parkinson's disease. It is conducting a Phase 1/2 clinical study of ATB200-02 to investigate pompe treatment paradigm in pompe patients. The company has strategic alliance with GlaxoSmithKline plc to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.

Gamida Cell Ltd., a clinical stage biopharmaceutical company, focuses on developing cell therapies to cure cancer, and rare and serious hematologic diseases in the United States, the European Union, and internationally. The company's lead product candidate is NiCord, a nicotinamide (NAM)-expanded cord blood cell therapy that is in Phase 3 clinical trials for use as a curative stem cell graft for patients in hematopoietic stem cell transplant. It is also developing NAM-NK, an innate immunotherapy of expanded natural killer cells, which is in Phase 1 clinical trials for the treatment of refractory non-Hodgkin lymphoma and multiple myeloma. The company was founded in 1998 and is headquartered in Jerusalem, Israel.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.